Johnson & Johnson Chair and CEO Joaquin Duato oversees the company’s medical device and pharmaceutical segments. [Photo courtesy of Johnson & Johnson]
J&J reported $94.2 billion in 2025 revenue, a 6% increase from $88.8 billion the year before. That total includes its Innovative Medicine pharmaceutical segment and J&J MedTech medical device segment, the latter of which brought in $33.8 billion in 2025 revenue.
J&J MedTech is the world’s second-largest medical device business, according to the 2025 Medical Design & Outsourcing Medtech Big 100 ranking by revenue. J&J MedTech trailed only Medtronic, which reported sales of $33.5 billion for fiscal 2025 and has yet to release its results for fiscal 2026, which ends in April.
Nitinol Innovation: Hear from device development experts at J&J, Boston Scientific, Medtronic and more who are working on nitinol-powered PFA systems
Recruiting and retaining top talent — both at the executive and engineering level — is crucial in the medtech industry, but employee compensation is kept secret in most cases. Medical Design & Outsourcing tracks and analyzes these pay figures when disclosed by major device developers and manufacturers.
Johnson & Johnson executive pay
J&J Chair and CEO Joaquin Duato received $32.8 million in total compensation for 2025, up 35% from $24.3 million the year before, according to the new disclosure.
Duato’s 2025 pay package included a $1.6 million salary, stock awards of $15 million, option awards of $6 million, a $4.3 million cash performance bonus and a $5.3 million change in pension value and non-qualified deferred compensation earnings.
He also received $601,231 in other compensation, including $161,687 worth of personal use of corporate aircraft and $367,977 for personal and home security services.
Johnson & Johnson EVP and CFO Joseph Wolk [Photo courtesy of Johnson & Johnson]
Wolk’s 2025 pay included a $1.2 million salary, $6.3 million in stock awards, option awards of $2.5 million, a $1.9 million cash performance bonus, a $2.5 million change in pension value and non-qualified deferred compensation earnings, and other compensation of $115,222.
J&J EVP and Innovative Medicine Worldwide Chair Jennifer Taubert received $14 million in 2025, up 25% from $11.2 million the year before.
Johnson & Johnson EVP and Innovative Medicine Worldwide Chair Jennifer Taubert [Photo courtesy of Johnson & Johnson]
J&J EVP of Innovative Medicine and R&D Dr. John Reed received $12.2 million in total compensation, a 36% increase from $9.3 million in 2024.
Reed’s 2025 compensation included a $1.2 million salary, $6.2 million in stock awards, option awards of $2.4 million, a $1.8 million cash performance bonus, a $458,000 change in pension value and non-qualified deferred compensation earnings and other compensation of $135,076.
Johnson & Johnson EVP and J&J MedTech Worldwide Chair Tim Schmid [Photo courtesy of Johnson & Johnson]
In 2024, Schmid received nearly $4.1 million for relocation costs to mov from Singapore to the U.S. and $3.8 million in move-related tax assistance after leaving his position as group chair of J&J MedTech Asia Pacific to lead J&J MedTech.
Schmid’s total pay package in 2025 included a salary of $942,308, $3.4 million in stock awards, option awards of $1.3 million, a $1.5 million cash performance bonus, and a $2 million change in pension value and non-qualified deferred compensation earnings.
More from Schmid: Leadership in Medtech
“Every year, we review the executive compensation structure to ensure that we are incentivizing strong results in a manner that is consistent with the values embodied in Our Credo,” the J&J Board of Directors Compensation & Benefits Committee said in the disclosure. “We actively solicit shareholder input regarding our executive compensation practices. The company’s 2025 Say on Pay vote received approximately 92% approval, reflecting strong shareholder support for our pay for performance alignment, proactive engagement, and continuous program refinement.”
The Compensation & Benefits Committee said the 2025 annual incentive results and payout factors exclude the company’s reversal of its $7 billion settlement charge related to its talcum litigation to avoid creating “a windfall for executives that’s inconsistent with [J&J’s] non-GAAP policies and past practices.”
Learn more about J&J and dozens of other surgical robotics developers in the 2026 MassDevice Surgical Robotics Special Report
Johnson & Johnson median worker pay and CEO pay ratio
The U.S. Securities and Exchange Commission requires publicly traded companies like J&J to calculate the gap between CEO compensation and pay for its median employee.
J&J’s median employee total compensation was $91,000, up 10% from $83,000 the year before. J&J said if exchange rates had not changed during 2025, the median wage would have been $89,000.
That median wage and Duato’s $32.7 million pay package put J&J’s CEO pay at 360 times more than the median worker, increasing the pay gap between CEO and median employees following a 293:1 pay gap ratio the year before.
J&J said that ratio is likely a conservative estimate and that the true pay gap between the CEO and median worker may be narrower.
At other medtech companies that offer more details about their median workers than required by the SEC pay disclosure rules, those median medtech workers often hold technical roles such as device design or engineering.
J&J investors will cast advisory “say-on-pay” votes on the company’s executive compensation practices at the April 23 annual meeting. Shareholders overwhelmingly voted in support of the company’s executive pay the year before.
More medtech compensation analysis for CEOs, top-paid executives and median workers
- Boston Scientific CEO pay rises again along with median employee pay
- Intuitive discloses CEO pay with new leader at the helm
- Medtronic discloses pay for Diabetes leaders ahead of MiniMed IPO
- Medline discloses executive pay and potential severance payouts ahead of IPO
- Medtronic reports double-digit pay hikes for CEO Geoff Martha and other top executives
- Philips CEO pay dropped in 2024 as Respironics recall fallout continued
- Siemens Healthineers reports higher pay for some executives, lower pay for others
- Henry Schein discloses pay hikes for top leaders
- Owens & Minor executive pay disclosure includes severance for C-suite ouster
- Alcon makes its case on executive pay after last year’s lack of investor support
- GE HealthCare executive compensation plunges after one-time spinoff awards
- Zimmer Biomet discloses pay packages for top executives and its median employee
- Edwards Lifesciences reports $14.6M in pay for CEO’s first full year; median employee pay jumps
- BD reports pay increases for some execs, decreases for others
- Baxter CEO pay surged before his departure — along with the median employee’s wage
